Vimarsana
Biggest News Aggregation in the World

Page 3 - Michael Yi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Yi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Yi Today - Breaking & Trending Today

Classical Sprouts: Sprouts at The Met! - Vimarsana News

Classical Sprouts: Sprouts at The Met!

The Child Spirits in the Metropolitan Opera's production of "The Magic Flute" gave us the inside scoop!

专访王振涛丨解析服务能力决定服务质量的居家养老模式 - Vimarsana News

专访王振涛丨解析服务能力决定服务质量的居家养老模式

本期节目将分享颐家(上海)医疗养老服务有限公司的经验和做法。

Source: yicai.com
China Digest: Deltaphone, Trinomab and Scivita Medical raise fresh capital - Vimarsana News

China Digest: Deltaphone, Trinomab and Scivita Medical raise fresh capital

China Digest: Deltaphone, Trinomab and Scivita Medical raise fresh capital Photo: Eric Prouzet/Unsplash April 26, 2021 Chinese industrial internet solutions startup Deltaphone, biopharmaceutical firm Trinomab Biotech, and Scivita Medical Technology, a medical devices manufacturer that focuses on endoscopes, have completed new funding rounds. Industrial internet startup Deltaphone closes $77m Series B Chinese industrial internet solutions startup Deltaphone has secured 500 million yuan ($77.1 million) in a Series B round to finance its continued product iterations and business expansion. The S...

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing - Vimarsana News

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing News provided by Share this article Share this article Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion) The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies CHENGDU, China, Feb. 22, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world's most...

China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial - Vimarsana News

China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial

Subscribe China’s Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial By Jane Byrne Clover Biopharmaceuticals today announced that it has raised US$230m in Series C financing, bringing to over US$400m the funds it has generated in the past 12 months. The round was co-led by GL Ventures, the early stage affiliate of Hillhouse Capital, and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.  Clover plans to initiate a ...